---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-001806"
form_type: "8-K"
ticker: "PMDI"
cik: "0000806517"
company_name: "PSYCHEMEDICS CORP"
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:40:30.323693+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Psychemedics reports flat FY2022 revenue; net loss widens to $0.19/sh; declares $0.07 dividend

## Summary
- FY2022 revenue $25.2M (+1% YoY); net loss $1.1M or ($0.19) diluted EPS vs loss $0.7M ($0.12) prior year.
- Q4 2022 revenue $5.7M (-11% YoY); net loss $0.7M or ($0.12) diluted EPS vs loss $1.6M ($0.29).
- Board declared $0.07 quarterly cash dividend, payable April 10, 2023 to holders of record March 31, 2023.
- Cash $4.8M, working capital $4.3M at year-end; equipment financing reduced to $0.6M.
- Management cites labor shortage and inflation challenges; domestic revenue up 4% in 2022.

## SEC filing metadata
- accession: 0001171843-23-001806
- form_type: 8-K
- ticker: PMDI
- cik: 0000806517
- company_name: PSYCHEMEDICS CORP
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/806517/000117184323001806/0001171843-23-001806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/806517/000117184323001806/f8k_032123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-001806
- JSON: https://secwatch.observer/filing/0001171843-23-001806.json
- Plain text: https://secwatch.observer/filing/0001171843-23-001806.txt

## Key facts
- Earnings Releases
  PSYCHEMEDICS CORP reported the quarter ended December 31, 2022 results: revenue $5.7 million, net income $0.7 million, EPS ($0.12) per diluted share.
  - Period: the quarter ended December 31, 2022
  - Revenue: $5.7 million
  - Net income: $0.7 million
  - EPS: ($0.12) per diluted share
  - Result: reported results
  source text: The Company’s revenue for the quarter ended December 31, 2022, was $5.7 million versus $6.4 million for the quarter ended December 31, 2021, a decrease of 11%. Net loss for the quarter ended December 31, 2022, was $0.7 million or ($0.12) per diluted share, versus net loss of $1.6 million or ($0.29) per diluted share, for the comparable period last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/806517/000117184323001806/0001171843-23-001806-index.htm
- Earnings Releases
  PSYCHEMEDICS CORP reported the year ended December 31, 2022 results: revenue $25.2 million, net income $1.1 million, EPS ($0.19) per diluted share.
  - Period: the year ended December 31, 2022
  - Revenue: $25.2 million
  - Net income: $1.1 million
  - EPS: ($0.19) per diluted share
  - Result: reported results
  source text: The Company's revenue for the year ended December 31, 2022, was $25.2 million versus $24.9 million for the year ended December 31, 2021, an increase of 1%. Net loss for the year ended December 31, 2022, was $1.1 million or ($0.19) per diluted share, versus net loss of $0.7 million or ($0.12) per diluted share, for the comparable period last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/806517/000117184323001806/0001171843-23-001806-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.